Acute passive cigarette smoke exposure and inhaled human insulin (Exubera®) pharmacokinetics

British Journal of Clinical Pharmacology

Volumn 65, Issue 6, 2008, Pages 864-870

  Fountaine, Robert ^a,b   Milton, Ashley ^b   Checchio, Tina ^b   Wei, Greg ^b   Stolar, Marilyn ^b   Teeter, John ^b   Jaeger, Rudolph ^c   Fryburg, David ^b  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c Environmental Medicine Inc   (United States)

Author keywords

Inhaled human insulin; Passive smoking; Pharmacokinetics

Indexed keywords

CIGARETTE SMOKE; COTININE; NICOTINE; PENTETIC ACID; RECOMBINANT HUMAN INSULIN; TECHNETIUM 99M;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CIGARETTE SMOKING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG SAFETY; EXPOSURE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; LUNG CLEARANCE; LUNG PERMEABILITY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; NORMAL HUMAN; PARAMETER; PASSIVE SMOKING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; STATISTICAL ANALYSIS; THORAX PAIN; VOMITING;

ABSORPTION; ADMINISTRATION, INHALATION; ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; CROSS-OVER STUDIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; TOBACCO; TOBACCO SMOKE POLLUTION;

EID: 43549106068     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03122.x     Document Type: Article

References (24)

1. Nelson E. The miseries of passive smoking. Hum Exp Toxicol 2001 20: 61 83.
2. Office of Environmental Health Hazard Assessment. Health Effects of Exposure to Environmental Tobacco Smoke. Final Report September 1997. Available at http://www.oehha.org/air/environmental_tobacco/finalets.html (last accessed March 2006).
3. Miller LG. Cigarettes and drug therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharm 1990 9: 125 35.
4. Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet 1999 36: 425 38.
5. Groth S, Mortensen J, Lange P, Vest S, Rossing N, Swift D. Effect of change in particle number on pulmonary clearance of aerosolized 99mTc-DTPA. J Appl Physiol 1989 66: 2750 5.
6. Effros RM, Mason GR. Measurements of pulmonary epithelial permeability in vivo. Am Rev Respir Dis 1983 27: S59 65.
7. Jones JG, Lawler P, Crawley JC, Minty BD, Hulands G, Veall N. Increased alveolar epithelial permeability in cigarette smokers. Lancet 1980 1: 66 8.
8. 113mIn-DTPA aerosol clearances in humans. Effects of smoking, hyperinflation, and in vitro oxidation. Am Rev Respir Dis 1987 136: 1112 6.
9. Mason GR, Uszler JM, Effros RM, Reid BA. Rapidly reversible alterations of pulmonary epithelial permeability induced by smoking. Chest 1983 83: 7 11.
10. Schmekel B, Borgstrom L, Wollmer P. Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers. Thorax 1992 46: 225 8.
11. 99mTc-DTPA acutely. Aust NZ J Med 1996 26: 513 8.
12. Barnett AH. Exubera inhaled insulin: a review. Int J Clin Pract 2004 58: 394 401.
13. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmaokinet 2004 43: 781 801.
14. Barnett AH, Lange P, Dreyer M, Serdarevic-Pehar M Exubera® Phase 3 Study Group. Long-term tolerability of inhaled human insulin (Exubera®) in patients with poorly controlled type 2 diabetes. Int J Clin Pract 2007 61: 1614 25.
15. Sha S, Becker RHA, Willavise SA, Schumacher DA, Lee JD, Carroll RS, Fryburg DA. The effect of smoking cessation on the absorption of inhaled insulin (Exubera®). Diabetes 2002 51 (Suppl. 2 538 (Abstract).
16. Becker RHA, Sha S, Frick AD, Fountaine RJ. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care 2006 29: 277 82.
17. Davis WA, Knuiman M, Kendall P, Grange V, Davis TME. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2004 27: 752 7.
18. Owens DR. Human insulin. Intermediate-acting insulin preparations 'initial ratio' method. In: Clinical Pharmacological Study in Normal Man, ed. Owens DR: MTD Press Limited, 1986 138.
19. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion Office on Smoking and Health. Deposition and absorption of tobacco smoke constituents. In: Surgeon General Report: Health Consequences Involuntary Smoking, Chapter 4, ed. Donald R. Washinton, DC: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion Office on Smoking and Health, 1986 177 224.
20. Wiedemann HP, Mahler DA, Loke J, Virgulto JA, Snyder P, Matthay RA. Acute effects of passive smoking on lung function and airway reactivity in asthmatic subjects. Chest 1986 89: 180 5.
21. Mahmud A, Feely J. Effects of passive smoking on blood pressure and aortic pressure waveform in healthy young adults - influence of gender. Br J Clin Pharmacol 2003 57: 37 43.
22. Hausberg M, Mark A, Winniford MD, Brown RE, Somers VK. Sympathetic and vascular effects of short-term passive smoke exposure in healthy nonsmokers. Circulation 1997 96: 282 7.
23. Kato M, Roberts-Thomson P, Phillips BG, Narkiewicz K, Haynes WG, Pesek CA, Somers VK. The effects of short-term passive smoke exposure on endothelium-dependent and independent vasodilation. J Hypertens 1999 17: 1395 401.
24. Leuenberger P, Schwartz J, Ackermann-Liebrich U, Blaser K, Bolognini G, Bongard JP, Brandli O, Braun P, Bron C, Brutsche M. Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Am J Respir Crit Care Med 1994 150: 1222 8.